According to a recently published report, the global Erythropoietin Stimulating Agents Market is expected to grow $7.4billion by 2022with the CAGR of 0.3% during 2015-2022. The segmentation of global erythropoietin stimulating agents market is based on products, application,and Region. The report on global erythropoietin stimulating agents market forecast 2015-2022 (products, application and region) provides detailed overview and predictive analysis of the market.

Detailed study on this Report :

The erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis. These EPO drugs are used for treatment of chemotherapy induced anemia. The global EPO agents market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV, and kidney failures. The cancer, HIV, kidney diseases are very chronic diseases and are responsible for large number of deaths worldwide. Over 80 % population in the world is dying from chronic diseases, 13 million are died in 2014 from cancer, more than 7.3 million are suffering from HIV, more than 4.7 million are suffering from kidney diseases and this facts is expected to rise in near future, these types of diseases cause anemia or lack of red blood cells in human body. An erythropoiesis stimulating agent or drug is a medicine which stimulates red blood cells protein erythropoiesis. They are used in conditions where reduced blood cells production causes anemia. The global erythropoietin stimulating agents market is driving with the rising number of anemia cases in the world. Increasing awareness of EOP therapies in the treatment of anemia also pushes the market upwards.

For Same Category Reports Visit Here:

Scope of the report

1. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET by products 2012 – 2022 ($ billion)
1.1. Epoetin-alfa
1.2. Epoetin-beta
1.3. Darbepoetin-alfa

2. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET by application2012 – 2022 ($ billion)
2.1. Cancer treatments
2.2. HIV treatments
2.3. Kidney disorders
2.4. others

3. GLOBAL ERYTHROPOIETIN STIMULATING AGENTS MARKET regional outlook 2012-2022($billion)
3.1. North America
3.2. Europe
3.3. Asia Pacific
3.4. Rest of the world

4. Company profiles
4.1. 3SBio
4.2. Amgen Inc.
4.3. Biocon
4.4. BioSidus
4.5. Celltrion, Inc
4.7. Hoffmann-La Roche
4.8. Intas Pharmaceuticals
4.9. Johnson and Johnson
4.10. LG Life Sciences Ltd.
4.11. Ranbaxy Laboratories Ltd.
4.12. Roche
4.14. Sandoz Hospira
4.15. Teva Pharmaceutical Industries Ltd.

Blog :

About Us:

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to  aid businesses identify market opportunities   optimize strategies.

Contact Us :

Jennifer Smith
Office 1094
109 Vernon House
Friar Lane
United Kingdom
Phone : +448081890034 (UK)
Email :
Website :